Azilsartan Kamedoxomil Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 40 mg, 80 mg
Reference Brands: Edarbi (USA)
Category:
Heart Disorder
Azilsartan kamedoxomil is available in Tablets
and strengths such as 40 mg, 80 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Azilsartan kamedoxomil is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Azilsartan kamedoxomil can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Azilsartan is an angiotensin II receptor blocker (ARB) used for the treatment of hypertension in adults. It is administered clinically in its prodrug form, azilsartan kamedoxomil, which is rapidly converted in the body to the active compound azilsartan after oral administration. By selectively blocking the angiotensin II type 1 (AT1) receptor, azilsartan prevents vasoconstriction and reduces aldosterone secretion, leading to effective and sustained blood pressure control. The drug was developed by Takeda and is marketed under the brand name Edarbi in multiple regions.
A key advantage of azilsartan is its strong and long-lasting antihypertensive effect, which supports once-daily dosing and consistent blood pressure reduction throughout the day. It is approved for use as monotherapy or in combination with other antihypertensive agents. Notably, azilsartan does not generally require dose adjustment in patients with mild to moderate renal or hepatic impairment, making it a convenient option for a broad patient population. Its favorable efficacy and safety profile have established azilsartan as a reliable choice in the long-term management of hypertension and the prevention of associated cardiovascular complications.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing